ArticleOncotarget2017
KLF15 promotes the proliferation and metastasis of lung adenocarcinoma cells and has potential as a cancer prognostic marker.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Abnormal expression of Krüppel-like transcription factors and their potential values in lung cancer.Heliyon · 2024Review
- KLF15 transcriptionally activates LINC00689 to inhibit colorectal cancer development.Communications biology · 2024Article
- Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.Cancer research · 2023Article
- Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming.Frontiers in pharmacology · 2023Review
- MiR-181a promotes cell proliferation and migration through targeting KLF15 in papillary thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Expression and Prognosis Value of the KLF Family Members in Colorectal Cancer.Journal of oncology · 2022Article
- DNA methylation ofAging · 2021Article
- Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis.Biology direct · 2021Article
- KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.Journal of experimental & clinical cancer research : CR · 2020Article
- EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.Nucleic acids research · 2020Article
- Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non-small cell lung cancer via the regulation of epithelial-to-mesenchymal transition.Experimental and therapeutic medicine · 2020Article
- OSluca: An Interactive Web Server to Evaluate Prognostic Biomarkers for Lung Cancer.Frontiers in genetics · 2020Article
- MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression.Cell proliferation · 2019Article
- HypermethylatedOncoTargets and therapy · 2019Article
- Identification of key genes associated with lung adenocarcinoma by bioinformatics analysis.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LADC)is a general form of non-small cell lung cancer that represents a significant threat to public health worldwide. The 5-year-survival rate for LADC is currently below 15%. The transcription factor KLF15, also called kidney-enriched KLF (KKLF), has been proven to play a role in inhibiting proliferation and diversification of carcinoma cells, including those of the endometrium, pancreas and breast, but the involvement of KLF15 in LADC has not previously been studied. In this study, we compared the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.